PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience
PharmaVentures acted as the exclusive advisor to Douglas Pharmaceuticals on its U.S. license agreement with Daré Bioscience, Inc.
London, UK, 06 September 2023
PharmaVentures is pleased to announce that it acted as the exclusive advisor to Douglas Pharmaceuticals on its U.S. license agreement with Daré Bioscience, Inc. (NASDAQ: DARE) to develop and commercialise R-131-2, a novel topical medicinal candidate for the treatment for cervical intraepithelial neoplasia.
Stephen Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted Douglas in finding a suitable U.S. partner for the development and commercialisation of R-131-2 and excited for the potential impact this pharmacological treatment can have on women affected with these conditions. We look forward to helping Douglas with more partnerships for R-131-2.”
Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported our long-standing client, Douglas Pharmaceuticals, through the discussion with Daré Bioscience. This is yet another exciting example of how PharmaVentures can help clients reach their partnering goals.”